<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:xmi="http://www.omg.org/XMI" xmlns:pos="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/pos.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmlns:cas="http:///uima/cas.ecore" xmlns:tweet="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/pos/tweet.ecore" xmlns:type8="http:///org/apache/uima/ruta/type.ecore" xmlns:morph="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/morph.ecore" xmlns:dependency="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/dependency.ecore" xmlns:type6="http:///de/tudarmstadt/ukp/dkpro/core/api/semantics/type.ecore" xmlns:type9="http:///org/apache/uima/trials/type.ecore" xmlns:noNamespace="http:///uima/noNamespace.ecore" xmlns:type="http:///de/tudarmstadt/ukp/dkpro/core/api/anomaly/type.ecore" xmlns:type7="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type.ecore" xmlns:type3="http:///de/tudarmstadt/ukp/dkpro/core/api/metadata/type.ecore" xmlns:type4="http:///de/tudarmstadt/ukp/dkpro/core/api/ner/type.ecore" xmlns:type5="http:///de/tudarmstadt/ukp/dkpro/core/api/segmentation/type.ecore" xmlns:type2="http:///de/tudarmstadt/ukp/dkpro/core/api/coref/type.ecore" xmlns:constituent="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/constituent.ecore" xmlns:chunk="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/chunk.ecore" xmi:version="2.0"><cas:NULL xmi:id="0"/><tcas:DocumentAnnotation xmi:id="2" sofa="1" begin="0" end="1514" language="x-unspecified"/><type9:ORR xmi:id="3" sofa="1" begin="1017" end="1020"/><type9:ORR xmi:id="4" sofa="1" begin="1022" end="1025"/><type9:ORR xmi:id="5" sofa="1" begin="1030" end="1033"/><type9:OSMean xmi:id="6" sofa="1" begin="1184" end="1200"/><cas:Sofa xmi:id="1" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="OBJECTIVE: To evaluate the efficacy of pegylated liposomal doxorubicin (PLD) and &#13;&#10;continuous infusion ifosfamide (IFO) in ovarian cancer patients who relapse&#13;&#10;within 1 year after first-line paclitaxel-platinum-based chemotherapy.&#13;&#10;METHODS: Patients were stratified according to treatment-free interval (TFI) (&lt;or&#13;&#10;&gt;or=6 months). PLD (40 mg/m(2), day 1), IFO (1700 mg/m(2), infusion days 1-3),&#13;&#10;and mesna were given every 28 days for 6-9 cycles. Primary endpoint was objective&#13;&#10;response rate (ORR). Secondary endpoints were response duration, progression free&#13;&#10;survival (PFS), overall survival (OS), and toxicity.&#13;&#10;RESULTS: There were 98 evaluable patients (58%, TFI&lt;6 months). Median number of&#13;&#10;cycles was 5 (range: 1-9). The frequency of grade 3/4 anemia, thrombocytopenia,&#13;&#10;and neutropenia was 7%, 3%, and 48%, respectively; febrile neutropenia was 3%. A &#13;&#10;low rate of grade 3/4 non-hematologic toxicities was reported, including&#13;&#10;nausea/vomiting (3/4%), hand-foot syndrome (2%), and mucositis (2%). The ORR was &#13;&#10;28% (41% and 19% in patients with TFI &gt;or=6, or &lt;6 months, respectively); rate of&#13;&#10;disease stabilization was 26%; response duration and median OS were 6 (2.4-26)&#13;&#10;and 14 (1-46) months, respectively.&#13;&#10;CONCLUSION: The combination of PLD and continuous IFO is a feasible and efficient&#13;&#10;treatment in patients with relapsed ovarian cancer, especially with TFI between 6&#13;&#10;and 12 months. This regimen may represent an alternative to platinum&#13;&#10;reintroduction and should be evaluated in a randomized trial."/><cas:View sofa="1" members="2 3 4 5 6"/></xmi:XMI>